HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CQP 201-403

belongs to class of 8-aminoergolines

Also Known As:

CQP-201-403; Sulfamide, N,N-dimethyl-N'-((8alpha)-6-propylergolin-8-yl)-

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Ergot Alkaloids: 208
    - Ergolines: 109
      - CQP 201-403: 4
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Ergolines: 109
      - CQP 201-403: 4

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/1989 - "This study suggests that CQP 201-403 may be of value in the treatment of Parkinson's disease." 01/01/1989 - "CQP 201-403 in Parkinson's disease: an open-label pilot study."
2.	Hyperprolactinemia 04/01/1988 - "CQP 201-403, a new dopamine agonist in the treatment of hyperprolactinemia." 10/01/1987 - "It is concluded that CV 205-502 and CQP 201-403 hold potential for the treatment of patients with hyperprolactinaemia and, possibly, also in patients with acromegaly."
3.	Tachycardia (Tachyarrhythmias) 05/15/1988 - "Qualitatively CQP 201-403 differs slightly from bromocriptine and apomorphine in its effects on the CNS (no influence on serotonin metabolism in the rat cortex; induction of masculine mounting behavior in rats) and the cardiovascular system of the dog (reflex tachycardia in response to a blood-pressure fall). "
4.	Acromegaly 10/01/1987 - "It is concluded that CV 205-502 and CQP 201-403 hold potential for the treatment of patients with hyperprolactinaemia and, possibly, also in patients with acromegaly."

Related Drugs and Biologics

1.	Dopamine Agonists (Dopamine Agonist)
2.	Serotonin (5 Hydroxytryptamine)
3.	Bromocriptine (Parlodel)
4.	Apomorphine
5.	quinagolide